Company Releases Early Data and Plans to Boost Dose in Duchenne Muscular Dystrophy Trial
PhotoLizM / Pixabay

Company Releases Early Data and Plans to Boost Dose in Duchenne Muscular Dystrophy Trial

According to a story from pm360online.com, the life sciences company Solid Biosciences has released some preliminary findings from its Phase 1/2 clinical trial of SGT-001. This investigational product is in…

Continue Reading Company Releases Early Data and Plans to Boost Dose in Duchenne Muscular Dystrophy Trial
Company Plans Extension Study for Phase 3 Trial of Amyotrophic Lateral Sclerosis Drug
source: pixabay.com

Company Plans Extension Study for Phase 3 Trial of Amyotrophic Lateral Sclerosis Drug

According to a story from pm360online.com, the Orion Corporation, a pharmaceutical company based in Finland, has recently announced that it plans to continue its Phase 3 trial of levosimendan as…

Continue Reading Company Plans Extension Study for Phase 3 Trial of Amyotrophic Lateral Sclerosis Drug

This Just In: Patient Reported Experiences are Important for Research in Osteogenesis Imperfecta

What is osteogenesis imperfecta? Osteogenesis imperfecta (OI) actually refers to a group of four distinct rare disorders- OI Type I, II, III, and IV. They're all characterized by brittle bones which…

Continue Reading This Just In: Patient Reported Experiences are Important for Research in Osteogenesis Imperfecta

Study Shows Treatment may be Effective for Chronic Kidney Disease but Increase Risk of Hyperkalemia

A recent study, called TOPCAT, evaluated the effects of spironolactone as a treatment for individuals living with Chronic Kidney Disease (CKD) who are also diagnosed with heart failure with preserved ejection fraction,…

Continue Reading Study Shows Treatment may be Effective for Chronic Kidney Disease but Increase Risk of Hyperkalemia
Importance of Patient-Centered Research in Familial Chylomicronemia Syndrome
source: pixabay.com

Importance of Patient-Centered Research in Familial Chylomicronemia Syndrome

Familial Chylomicronemia Syndrome (FCS) Is a rare disease caused by malfunctioning lipoprotein lipase. This results in a buildup of triglycerides in the body's plasma. FCS can cause pancreatitis, memory loss, nerve…

Continue Reading Importance of Patient-Centered Research in Familial Chylomicronemia Syndrome

You Can Provide Suggestions for the FDA’s Revision of their Rare Disease Research Guidelines

Time for Revision Like many things in this world, research for rare diseases such as Spinal Muscular Atrophy (SMA), Multiple Sclerosis, and Duchenne Muscular Dystrophy (DMD) has evolved substantially in recent years. This evolution…

Continue Reading You Can Provide Suggestions for the FDA’s Revision of their Rare Disease Research Guidelines
Possible Treatment for Niemann-Pick Disease Type C Performs Well in Clinical Trial
DarkoStojanovic / Pixabay

Possible Treatment for Niemann-Pick Disease Type C Performs Well in Clinical Trial

According to a story from labiotech.eu, the biotechnology company Orphazyme has been developing an experimental therapy for Niemann-Pick disease type C. In a recent Phase 2/3 clinical trial, the investigational…

Continue Reading Possible Treatment for Niemann-Pick Disease Type C Performs Well in Clinical Trial

Results from Phase II/III Trial Bring Hope for FDA Approval for New Niemann-Pick Disease Type C Treatment

Niemann-Pick Disease is a genetic lysosomal storage disease. Lipids accumulate in the lysosomes of cells, causing debilitating symptoms. There are three forms of the disease- A, B, and C. Each…

Continue Reading Results from Phase II/III Trial Bring Hope for FDA Approval for New Niemann-Pick Disease Type C Treatment

Yeast May be the Key to Uncovering Treatments for Homocystinuria and Other Metabolic Conditions

There is a great unmet medical need for patients living with metabolic disorders. There are few approved treatments for these conditions and many are fatal. These diseases include phenylketonuria, homocystinuria, tyrosinemia, and maple syrup…

Continue Reading Yeast May be the Key to Uncovering Treatments for Homocystinuria and Other Metabolic Conditions